Skip to content

A verification study of safety evaluation of excessive the test food consumption in humans

A verification study of safety evaluation of excessive the test food consumption in humans: A randomized double-blind placebo-controlled trial - A verification study of safety evaluation of excessive the test food consumption in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000041294
Enrollment
20
Registered
2020-08-03
Start date
2020-08-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Duration: Four weeks Test food: Capsule containing lipid-soluble polyphenol Administration: Take five capsules per day after breakfast with water. *If you forget to take the test food, take it

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult subjects 2. Subjects who are judged as eligible to participate in the study by the physician

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 5. Subjects currently regularly taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, breast-feeding, and planning to become pregnant 8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 9. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
1. Incidence of side effects 2. Incidence of adverse events

Secondary

MeasureTime frame
1. Physical examination 2. Urinalysis 3. Blood test 4. Original questionnaires 5. The measured values of the total score of self-administered dementia checklist (SDC), and the score of cognitive function and life function at two and four weeks after the start of test-food consumption 6. The change of the total score of SDC, and the score of cognitive function and life function at two and four weeks after the start of test-food consumption 7. The measured value of BDNF at four weeks after the start of test-food consumption 8. The change of BDNF at four weeks after the start of test-food consumption 9. The measured values of all of the total score of SDC at two and four weeks after the start of test-food consumption

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026